Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
106.06
-7.28 (-6.42%)
At close: Jan 15, 2026, 4:00 PM EST
106.11
+0.05 (0.05%)
Pre-market: Jan 16, 2026, 5:32 AM EST
Rhythm Pharmaceuticals Revenue
Rhythm Pharmaceuticals had revenue of $51.30M in the quarter ending September 30, 2025, with 54.28% growth. This brings the company's revenue in the last twelve months to $174.33M, up 54.92% year-over-year. In the year 2024, Rhythm Pharmaceuticals had annual revenue of $130.13M with 68.06% growth.
Revenue (ttm)
$174.33M
Revenue Growth
+54.92%
P/S Ratio
38.73
Revenue / Employee
$616,021
Employees
283
Market Cap
7.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 130.13M | 52.70M | 68.06% |
| Dec 31, 2023 | 77.43M | 53.79M | 227.56% |
| Dec 31, 2022 | 23.64M | 20.48M | 649.46% |
| Dec 31, 2021 | 3.15M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RYTM News
- 6 days ago - Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones - GlobeNewsWire
- 5 weeks ago - Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster - Seeking Alpha
- 5 weeks ago - Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript - Seeking Alpha
- 5 weeks ago - Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise - Benzinga
- 5 weeks ago - Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome - GlobeNewsWire
- 5 weeks ago - Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome - GlobeNewsWire
- 7 weeks ago - Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress - Seeking Alpha
- 2 months ago - Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025 - GlobeNewsWire